A Phase 1 interventional study of Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(4 hours) and Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(6 hours) in Acute-On-Chronic Liver Failure, sponsored by Third Affiliated Hospital, Sun Yat-Sen University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by Third Affiliated Hospital, Sun Yat-Sen University · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University — 6 open to participants now, 8 under way, none of them phase 3. Acute-On-Chronic Liver Failure · Third Affiliated Hospital, Sun Yat-Sen University.
Among the 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 1, and was the 11th registered.
167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.
Browse Acute-On-Chronic Liver Failure studies →6 of the 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University are open now, in 1 country. Recruiting first, the newest first:
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18–70
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 20–60
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18–65
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18–65
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 12–65
By country, each count listing its studies:
Of the 32 Acute-On-Chronic Liver Failure studies recruiting now, 11 (34%) set no upper age limit and 15 (47%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 4 1
First in 2019; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 15 is below the median of 73 across 96 interventional studies indexed under Acute-On-Chronic Liver Failure.
Median enrollment 60 across the 11 interventional studies, 250 across the 2 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Third Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 134 studies on the registry; 35 are open to participants now.
3 of the studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06996392Third Affiliated Hospital, Sun Yat-Sen UniversityPhase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure | 2026-12-31 |
| NCT07409259Third Affiliated Hospital, Sun Yat-Sen UniversityPT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure | 2027-08-31 |
| NCT06562803Third Affiliated Hospital, Sun Yat-Sen UniversityEfficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this Phase I clinical trial is to evaluate the safety and efficacy of combining the QH-1A bioartificial liver device with mesenchymal stem cells(MSCs) for blood purification in treating patients with acute-on-chronic liver failure, and to determine the optimal treatment duration and frequency for Phase II. The study will enroll patients aged 18 to 65 years who meet the diagnostic criteria for acute-on-chronic liver failure as outlined in the 2024 Chinese Liver Failure Clinical Guidelines.
The main questions this study aims to answer are:
Participants will be screened within 14 days before their first treatment and will be allocated into one of four groups based on treatment duration and frequency:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The 4-hour group will receive a single biological artificial liver treatment for 4 hours (±15 minutes).
Combination Product: Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(4 hours)
The 6-hour group will receive a single biological artificial liver treatment for 6 hours (±15 minutes).
Combination Product: Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(6 hours)
The 8-hour group will receive a single biological artificial liver treatment for 8 hours (±15 minutes).
Combination Product: Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(8 hours)
The Safety Evaluation Committee will determine the maximum tolerable treatment duration based on the 28-day safety observation outcomes from the 4-, 6-, and 8-hour groups. This duration will then be adopted as the treatment time for the multiple-treatment group. Subjects in the multiple-treatment group will undergo 2-3 treatments at this maximum duration, with an interval of 3 (±1) days between sessions.
Combination Product: Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification(Multiple-treatment)
The 4-hour group treatment session lasts 4 hours (±15 minutes). In the HBAL mode of the combined bioartificial liver device QH-1A, blood is initially filtered to separate the plasma, which is then pumped into a bioreactor. In this study, this bioreactor is uniquely filled with immortalized mesenchymal stem cells (PT-MSCs) optimized for blood purification. These cells are cultured to adhere to the outer surface of hollow fibers within the bioreactor, creating a stable and efficient living interface that continuously secretes bioactive factors such as exosomes.After passing through the bioreactor, the plasma is re-filtered and then returned to the patient's circulation via a dedicated pump.
After the three subjects in the 4-hour group completed their 4-week follow-up, the Safety Evaluation Committee convened a meeting to review the safety data and determine whether to proceed with the recruitment for the 6-hour group.The 6-hour group treatment session lasts 6 hours (±15 minutes).The treatment procedure is identical to that of the 4-hour group.
After the three subjects in the 6-hour group completed their 4-week follow-up, the Safety Evaluation Committee convened a meeting to review the safety data and determine whether to proceed with the recruitment for the 8-hour group. The 8-hour group treatment session lasts 8 hours (±15 minutes).The treatment procedure is identical to that of the 4-hour group.
Subjects in the multiple-treatment group will receive 2-3 sessions of bioartificial liver treatment; the number of sessions will be determined by the investigators based on the subjects' clinical needs. The treatment duration for each session will be set as the maximum tolerable period, as confirmed by the Safety Evaluation Committee based on 28-day safety observations from the 4-hour, 6-hour, and 8-hour groups. Each treatment session is administered following the procedure applied to patients in the group with the optimal tolerability duration.
Survival rate
Time frame: 28-day
Combined Bioartificial Liver Device QH-1A Equipment Performance Pass Rate
Pass Criteria: If all items on the trial medical device evaluation are rated as "Yes," the device's performance is deemed acceptable. If any evaluation item is rated as "No," the device's performance is considered unacceptable. Reasons for any "No" ratings must be documented.
Time frame: Day 1
Changes from the baseline in Child-Pugh grade
The Child-Pugh classification evaluation indicators consist of hepatic encephalopathy, ascites, total bilirubin, albumin, and prolonged PT time. The scoring and classification of the severity of Child-Pugh liver diseases are as follows:Grade A is 5 to 6 points. Grade B is 7 to 9 points. Grade C is 10 to 15 points. The higher the score, the worse the liver function.
Time frame: 28-day
Changes from the baseline in COSSH-ACLF IIs
The Chinese Severe Hepatitis B Study Group (COSSH), based on a multicenter, open-label large cohort study, has established a novel prognostic scoring system for hepatitis B virus (HBV)-ACLF: COSSH-ACLF II s. A score of less than 7.4 indicates a low-risk group, a score between 7.4 and 8.4 indicates a moderate-risk group, and a score greater than 8.4 indicates a high risk of 28- and 90-day mortality.
Time frame: 28-day
Changes from the baseline in MELD score
The MELD score (Model for End-Stage Liver Disease) is a scoring system used to assess the urgency of liver transplantation in chronic liver disease patients. The MELD score typically ranges from 6 to 40, with higher scores indicating more severe disease and a greater need for liver transplantation.
Time frame: 28-day
The rate of bridging liver transplantation
Time frame: 28-day
Incidence of adverse events and serious adverse events
All treatment-related adverse events will be assessed by CTCAE v5.0.
Time frame: 28-day
Number of participants with positive infectious pathogens in the return fluid
After each treatment session (0-15 minutes post-treatment), the return fluid from the bioreactor will be collected for testing of infectious pathogens (bacteria, fungi) and endotoxins.
Time frame: Day1
Number of participants with positive replicative lentivirus in the blood
blood samples were collected for the detection of replicative lentivirus.
Time frame: Day1,Day28
Number of participants in whom mesenchymal stem cell shedding was detected in the return fluid
During each treatment process, return fluid is collected at the front and back of the reactor at designated time points. Techniques such as flow cytometry and real-time fluorescence quantitative PCR are used to assess the shedding of mesenchymal stem cells.
Time frame: Day1
Changes from the baseline in immunogenicity indicators
During the observational study, changes in immunogenicity indicators were monitored to evaluate the immunogenicity of the investigational product. The immunogenicity indicators included immunoglobulins (IgM, IgG, IgA, IgE), complements (C3, C4), lymphocyte subset analysis (CD3+ T cell count and percentage, CD4+ T cell count and percentage, CD8+ T cell count and percentage), and cytokines (IL-2, IL-6, IL-8, IL-10, TNF-α, IFN-γ). Blood samples were collected for immunogenicity assessment at the following time points: before each machine-based treatment (-30 min to 0 min), 7±1 days, 28±3 days.
Time frame: Day1, Day7,Day28
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acute-On-Chronic Liver Failure →
Third Affiliated Hospital, Sun Yat-Sen University →